The Cantera: An Epic Learning Ring Cycle for Young Haematologists

por Younes, Anas
Publicado 2019

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma

por Samad, Nousheen, Younes, Anas
Publicado 2010

Histone deacetylase inhibitors in Hodgkin lymphoma

por Buglio, Daniela, Younes, Anas
Publicado 2010

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances

por Derenzini, Enrico, Younes, Anas
Publicado 2011

Immune Checkpoint Inhibition in Hodgkin Lymphoma

por Moy, Ryan H., Younes, Anas
Publicado 2018

Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy

por Carbone, Antonino, Gloghini, Annunziata, Kwong, Yok-Lam, Younes, Anas
Publicado 2014

A novel immunomodulatory and molecularly targeted strategy for refractory Hodgkin's lymphoma

por Subbiah, Vivek, Brown, Robert E., McGuire, Mary F., Buryanek, Jamie, Janku, Filip, Younes, Anas, Hong, David
Publicado 2013

Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma

por Portelinha, Ana, da Silva Ferreira, Mariana, Erazo, Tatiana, Jiang, Man, Asgari, Zahra, de Stanchina, Elisa, Younes, Anas, Wendel, Hans-Guido
Publicado 2023

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial

por Oki, Yasuhiro, Kelly, Kevin R, Flinn, Ian, Patel, Manish R., Gharavi, Robert, Ma, Anna, Parker, Jefferson, Hafeez, Amir, Tuck, David, Younes, Anas
Publicado 2017

Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols

por Greaves, Wesley, Xiao, Lianchun, Sanchez-Espiridion, Beatriz, Kunkalla, Kranthi, Dave, Kunal S, Liang, Cynthia S, Singh, Rajesh R, Younes, Anas, Medeiros, L Jeffrey, Vega, Francisco
Publicado 2012

Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma

por Mondello, Patrizia, Derenzini, Enrico, Asgari, Zahra, Philip, John, Brea, Elliott J., Seshan, Venkatraman, Hendrickson, Ronald C., de Stanchina, Elisa, Scheinberg, David A., Younes, Anas
Publicado 2017

NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death

por Liu, Yuxuan, Mondello, Patrizia, Erazo, Tatiana, Tannan, Neeta Bala, Asgari, Zahra, de Stanchina, Elisa, Nanjangud, Gouri, Seshan, Venkatraman E., Wang, Shenqiu, Wendel, Hans-Guido, Younes, Anas
Publicado 2018

ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors

por Portelinha, Ana, Thompson, Scott, Smith, Roger A., Da Silva Ferreira, Mariana, Asgari, Zahra, Knezevic, Andrea, Seshan, Venkatraman, de Stanchina, Elisa, Gupta, Sandeep, Denis, Louis, Younes, Anas, Reddy, Sanjeeva
Publicado 2021

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma

por Younes, Anas, Salles, Gilles, Martinelli, Giovanni, Bociek, Robert Gregory, Barrigon, Dolores Caballero, Barca, Eva González, Turgut, Mehmet, Gerecitano, John, Kong, Oliver, Pisal, Chaitali Babanrao, Tavorath, Ranjana, Kim, Won Seog
Publicado 2017

A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma

por Blum, Kristie A., Supko, Jeffrey G., Maris, Michael B., Flinn, Ian W., Goy, Andre, Younes, Anas, Bobba, Suresh, Senderowicz, Adrian M., Efuni, Sergey, Rippley, Ronda, Colak, Gozde, Trojer, Patrick, Abramson, Jeremy S.
Publicado 2022

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation

por Hodkinson, Brendan P., Schaffer, Michael, Brody, Joshua D., Jurczak, Wojciech, Carpio, Cecilia, Ben-Yehuda, Dina, Avivi, Irit, Forslund, Ann, Özcan, Muhit, Alvarez, John, Ceulemans, Rob, Fourneau, Nele, Younes, Anas, Balasubramanian, Sriram
Publicado 2020

A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma

por Qualls, David, Lam, Hiu Ying, Whiting, Karissa, Kumar, Anita, Matasar, Matthew, Owens, Colette, Nichols, Chelsea, Espeleta, James A, Qiu, Annie, Subzwari, Sarima, Biggar, Erin, Seshan, Venkatraman, Salles, Gilles, Younes, Anas, Batlevi, Connie
Publicado 2022

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma

por Younes, Anas, Burke, John M., Diefenbach, Catherine, Ferrari, Silvia, Khan, Cyrus, Sharman, Jeff P., Tani, Monica, Ujjani, Chaitra, Vitolo, Umberto, Yuen, Sam, Raval, Aparna, Shivhare, Mahesh, Nielsen, Tina G., Sellam, Gila, Gilbertson, Michael
Publicado 2022

A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials

por Kostakoglu, Lale, Martelli, Maurizio, Sehn, Laurie H., Davies, Andrew, Trněný, Marek, Herold, Michael, Vitolo, Umberto, Hiddemann, Wolfgang, Trotman, Judith, Knapp, Andrea, Mattiello, Federico, Nielsen, Tina G., Sahin, Deniz, Sellam, Gila, Ward, Carol, Younes, Anas
Publicado 2023

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma

por Younes, Anas, Burke, John M., Cheson, Bruce D., Diefenbach, Catherine S., Ferrari, Silvia, Hahn, Uwe H., Hawkes, Eliza A., Khan, Cyrus, Lossos, Izidore S., Musuraca, Gerardo, Tani, Monica, Vitolo, Umberto, Yuen, Sam, Raval, Aparna, Shivhare, Mahesh, Nielsen, Tina G., Sellam, Gila, Sharman, Jeff P.
Publicado 2022